Get the Stockscreener App
0.3979
1.63%
-0.0066
After Hours:
.38
-0.0179
-4.50%
Cognition Therapeutics Inc stock is traded at $0.3979, with a volume of 1.82M.
It is down -1.63% in the last 24 hours and down -29.56% over the past month.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.
See More
Previous Close:
$0.4045
Open:
$0.405
24h Volume:
1.82M
Relative Volume:
1.39
Market Cap:
$15.83M
Revenue:
-
Net Income/Loss:
$-22.83M
P/E Ratio:
-0.4627
EPS:
-0.86
Net Cash Flow:
$-20.87M
1W Performance:
-9.57%
1M Performance:
-29.56%
6M Performance:
-84.40%
1Y Performance:
-60.60%
1-Day Range:
$0.375
$0.4085
1-Week Range:
$0.375
$0.4791
52-Week Range:
$0.34
$2.95
Cognition Therapeutics Inc Stock (CGTX) Company Profile
Name
Cognition Therapeutics Inc
Sector
Industry
Phone
412-481-2210
Address
2403 SIDNEY STREET, PITTSBURGH
Compare CGTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CGTX
Cognition Therapeutics Inc
|
0.3979 | 15.83M | 0 | -22.83M | -20.87M | -0.86 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
|
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
|
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
Cognition Therapeutics Inc Stock (CGTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-30-24 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Nov-03-21 | Initiated | B. Riley Securities | Buy |
| Nov-03-21 | Initiated | Oppenheimer | Outperform |
Cognition Therapeutics Inc Stock (CGTX) Latest News
Cognition Therapeutics Announces all Participants have - GlobeNewswire
Cognition Therapeutics concludes Phase 2 DLB study - Investing.com
Cognition Therapeutics provided an update on Phase 2 ‘SHINE’ study analysis - Yahoo Finance
Cognition Therapeutics’ Analysis Correlates Biomarker Changes with Cognitive Benefit in Alzheimer’s Population - GlobeNewswire
Cognition Therapeutics Reports Financial Results for the Third Quarter 2024UNAUDITED – On November 13, 2024, Cognition Therapeutics, Inc. (NASDAQ: CGTX) disclosed its financial results for the third quarter ending September 30, 2024. Within the detai - Defense World
Chardan Capital Reaffirms Buy Rating for Cognition Therapeutics (NASDAQ:CGTX) - Defense World
Life Sciences Investor Forum: Presentations Now Available for Online Viewing - The Manila Times
Cognition Therapeutics Inc Reports Q3 2024 GAAP EPS of $(0.25), Missing Estimates; Net Loss Widens to $9.9 Million - GuruFocus.com
Cognition Therapeutics Reports Promising Q3 2024 Results - TipRanks
Cognition Therapeutics Reports Financial Results for the - GlobeNewswire
Cognition Therapeutics Reports Financial Results for the Third Quarter 2024 and Provides Business and Clinical Update - Yahoo Finance
Cognition Therapeutics to Present at Zacks SCR Life Sciences Investor Forum - The Manila Times
Analysts Set Cognition Therapeutics, Inc. (NASDAQ:CGTX) PT at $8.00 - Defense World
Cognition Therapeutics stock rated Buy, target held amid CT1812 data By Investing.com - Investing.com UK
November’s Small-Cap Treasures: 3 Stocks Poised for Growth - MarketBeat
Cognition Therapeutics (NASDAQ:CGTX) Earns Buy Rating from Chardan Capital - Defense World
Cognition Therapeutics Presents Poster of Participant - GlobeNewswire
Cognition Therapeutics Presents Poster of Participant Demographics from Phase 2 Dementia with - The Bakersfield Californian
Cognition Therapeutics Presents Poster of Participant Demographics from Phase 2 Dementia with Lewy Bodies Study at CTAD - Yahoo Finance
Global Neurological Biomarkers Market to Surpass USD 16 Billion Mark by 2030 | DelveInsight - PR Newswire
Cognition Therapeutics reports potential Alzheimer's treatment breakthrough By Investing.com - Investing.com South Africa
Cognition Therapeutics reports potential Alzheimer's treatment breakthrough - Investing.com
Cognition Therapeutics Announces Results of Pre-specified Analysis of SHINE Study Data Presented at CTAD - GlobeNewswire
Cognition Therapeutics (CGTX) Announces Results of Pre-specified Analysis of SHINE Study Data Presented at CTAD - StreetInsider.com
Dementia Associated With Alzheimer’s Disease Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers - The Globe and Mail
Dementia Associated With Alzheimer's Disease Pipeline - openPR
Cognition Therapeutics (NASDAQ:CGTX) versus Ocugen (NASDAQ:OCGN) Head-To-Head Survey - Defense World
Analyses from Cognition’s Positive Phase 2 ‘SHINE’ Study of - GlobeNewswire
Analyses from Cognition’s Positive Phase 2 ‘SHINE’ Study of CT1812 in Mild-to-Moderate ... - The Bakersfield Californian
Cognition Therapeutics Releases New Episode of - GlobeNewswire
Cognition Therapeutics Releases New Episode of “Conversations” Podcast: Executing Clinical Research in Dementia with Lewy Bodies (DLB) - Yahoo Canada Finance
Tau Inhibitors Clinical Trial Pipeline Analysis Demonstrates 25+ Key Companies At The Horizon Expected To Transform The Treatment Paradigm, Assesses D... - MENAFN.COM
Tau Inhibitors Clinical Trial Pipeline Analysis - GlobeNewswire
Tau Inhibitors Clinical Trial Pipeline Analysis Demonstrates 25+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight - India Shorts
Cognition Therapeutics Inc (CGTX) Q2 2024 Earnings Call Highlights: Promising Alzheimer's Trial ... By GuruFocus - Investing.com Canada
Cognition Therapeutics stock hits 52-week low at $0.4 - Investing.com
VEGFR-2 Antagonists Clinical Trial Pipeline Insights Featuring 25+ Companies | DelveInsight - GlobeNewswire
Cognition Therapeutics stock hits 52-week low at $0.4 By Investing.com - Investing.com South Africa
Alzheimer's Disease Clinical Trials 2024: EMA, PDMA, FDA - openPR
Cognition Therapeutics Inc (CGTX) presents a great opportunity, but the stock is slightly undervalued - US Post News
Cognition Therapeutics Will Participate in the Roth Healthcare Opportunities Conference - ForexTV.com
Cognition Therapeutics Inc (CGTX)’s Day in Review: Closing at 0.47, Up by 11.36 - The Dwinnex
Cognition Therapeutics Supports Lewy Body Dementia Awareness Month and the Need for Improved - The Bakersfield Californian
Cognition Therapeutics Supports Lewy Body Dementia - GlobeNewswire
Cognition Therapeutics Highlights CT1812 Potential in CNS Disorders - TipRanks
Cognition Therapeutics, Inc. (NASDAQ:CGTX) Sees Large Decrease in Short Interest - Defense World
Cognition Therapeutics Inc (CGTX) Stock: A Year of Decreases and Increases - The InvestChronicle
Trading Day Review: Cognition Therapeutics Inc (CGTX) Loses Momentum, Closing at 0.41 - The Dwinnex
Conduit Pharmaceuticals Inc (CDT) expanding its growth trajectory ahead - SETE News
Capricor Therapeutics rockets on plan to file BLA for full approval of deramiocel - The Pharma Letter
Point72 DIFC Ltd Acquires New Holdings in The Carlyle Group Inc. (NASDAQ:CG) - Defense World
Cognition Therapeutics Inc Stock (CGTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):